Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 5, pp 919–923 | Cite as

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy

  • Marta Simó
  • Andreas A. Argyriou
  • Miquel Macià
  • Gerard Plans
  • Carles Majós
  • Noemi Vidal
  • Miguel Gil
  • Jordi Bruna
Original Article

Abstract

Purpose

A prospective, two-stage phase II trial with octreotide in patients with recurrent high-grade meningioma was conducted. The radiographic partial response (RPR) was set as the primary study endpoint, whereas progression-free survival at 6 months (PFS6) was defined as the secondary endpoint.

Methods

Nine patients (eight men; median age 65) with histological high-grade meningioma (five with grade II and four with grade III) and progression after prior surgery and radiotherapy were included. All had positive brain octreotide SPECT scanning. Octreotide was administered intramuscularly once every 28 days at a dose of 30 mg for the first two cycles and 40 mg for subsequent cycles until progression. Magnetic resonance imaging was performed every 3 months. Progression and RPR were defined as an increase of ≥25 % and as a decrease of ≥50 % in two-dimensional maximum diameters, respectively.

Results

Patients received a median of three octreotide cycles (range 1–8) without grade ≥2 toxicities. No RPRs were observed. Stable disease was the best response in 33.3 % (n = 3). All patients had progressive disease at 10 months of follow-up. Median time to progression was 4.23 months (range 1–9.4), and the PFS6 was 44.4 % (n = 4).

Conclusion

Our study failed to provide evidence to support the use of monthly long-acting somatostatin analogue schedule in recurrent high-grade meningiomas, as none of our patients demonstrated RPR. The modest median PFS of 4–5 months along with the unknown natural history of recurrent meningiomas render the use of this therapy against these aggressive brain tumors uncertain.

Keywords

High-grade meningioma Recurrent meningioma Meningioma Somatostatin Octreotide 

References

  1. 1.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 14(Suppl 5):v1–v49PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99(3):307–314PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM (2005) Epidemiology of intracranial meningioma. Neurosurgery 57(6):1088–1095PubMedCrossRefGoogle Scholar
  4. 4.
    Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A (2007) Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology 27(2):114–120PubMedCrossRefGoogle Scholar
  5. 5.
    Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, Vecht C (2008) Meningioma. Crit Rev Oncol Hematol 67(2):153–171PubMedCrossRefGoogle Scholar
  6. 6.
    Mawrin C, Perry A (2010) Pathological classification and molecular genetics of meningiomas. J Neurooncol 99(3):379–391PubMedCrossRefGoogle Scholar
  7. 7.
    Chamberlain MC, Barnholtz-Sloan JS (2011) Medical treatment of recurrent meningiomas. Expert Rev Neurother 11(10):1425–1432PubMedCrossRefGoogle Scholar
  8. 8.
    Alexiou GA, Gogou P, Markoula S, Kyritsis AP (2010) Management of meningiomas. Clin Neurol Neurosurg 112(3):177–182PubMedCrossRefGoogle Scholar
  9. 9.
    Chamberlain MC (2012) The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma. Curr Opin Oncol 24(6):666–671PubMedCrossRefGoogle Scholar
  10. 10.
    Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD (2010) Medical therapies for meningiomas. J Neurooncol 99(3):365–378PubMedCrossRefGoogle Scholar
  11. 11.
    Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Somatostatin analogs: future directions. Metabolism 45(8 Suppl 1):104–106PubMedCrossRefGoogle Scholar
  12. 12.
    Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66(1–2):155–166PubMedCrossRefGoogle Scholar
  13. 13.
    García-Luna PP, Relimpio F, Pumar A, Pereira JL, Leal-Cerro A, Trujillo F, Cortés A, Astorga R (1993) Clinical use of octreotide in unresectable meningiomas. A report of three cases. J Neurosurg Sci 37(4):237–241PubMedGoogle Scholar
  14. 14.
    Jaffrain-Rea ML, Minniti G, Santoro A, Bastianello S, Tamburrano G, Gulino A, Cantore G (1998) Visual improvement during octreotide therapy in a case of episellar meningioma. Clin Neurol Neurosurg 100(1):40–43PubMedCrossRefGoogle Scholar
  15. 15.
    Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69(10):969–973PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC (2011) Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-Oncology 13(5):530–535PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Brem SS, Bierman PJ, Brem H, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Fine HA, Friedman A, Glass J, Grossman SA, Heimberger AB, Junck L, Levin V, Loeffler JJ, Maor MH, Narayana A, Newton HB, Olivi A, Portnow J, Prados M, Raizer JJ, Rosenfeld SS, Shrieve DC, Sills AK Jr, Spence AM, Vrionis FD (2011) Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Cancer Netw 9:352–400Google Scholar
  18. 18.
    Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, Fahlbusch R (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86(5):840–844PubMedCrossRefGoogle Scholar
  19. 19.
    Loven D, Hardoff R, Sever ZB, Steinmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Nonresectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221–226PubMedCrossRefGoogle Scholar
  20. 20.
    Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol 104(3):765–771PubMedCrossRefGoogle Scholar
  21. 21.
    Chamberlain MC (2012) Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 107(2):315–321PubMedCrossRefGoogle Scholar
  22. 22.
    von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S (2003) Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95(6):437–448CrossRefGoogle Scholar
  23. 23.
    Chamberlain MC, Glantz MJ (2008) Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113(8):2146–2151PubMedCrossRefGoogle Scholar
  24. 24.
    Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C (2008) Antitumor effects of somatostatin. Mol Cell Endocrinol 286(1–2):230–237PubMedCrossRefGoogle Scholar
  25. 25.
    Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, Höllt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6(5):1865–1874PubMedGoogle Scholar
  26. 26.
    Buscail L, Delesque N, Estève JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C (1994) Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91(6):2315–2319PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Schulz C, Mathieu R, Kunz U, Mauer UM (2011) Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus 30(5):E11PubMedGoogle Scholar
  28. 28.
    Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P (2014) Historical benchmarks for medical therapy trials in surgery-and radiation-refractory meningioma: RANO review. Neuro-Oncology (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Marta Simó
    • 1
  • Andreas A. Argyriou
    • 2
  • Miquel Macià
    • 1
  • Gerard Plans
    • 1
  • Carles Majós
    • 1
    • 3
  • Noemi Vidal
    • 1
  • Miguel Gil
    • 1
  • Jordi Bruna
    • 1
  1. 1.Neuro-Oncology UnitHospital Universitari de Bellvitge-ICO Duran i Reynals and Institut de Diagnòstic per la ImatgeL’Hospitalet del LlobregatSpain
  2. 2.Department of NeurologySaint Andrew’s General Hospital of PatrasPatrasGreece
  3. 3.Centro de Investigación en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)Cerdanyola del VallèsSpain

Personalised recommendations